Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports

被引：0
作者：
Mori, Shintaro [1 ]
Matsuo, Tomohiro [1 ]
Honda, Hiroyuki [1 ]
Araki, Kyohei [1 ]
Mitsunari, Kensuke [1 ]
Ohba, Kojiro [1 ]
Mochizuki, Yasushi [1 ]
Imamura, Ryoichi [1 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Urol, 1-7-1 Sakamoto Machi, Nagasaki, Nagasaki 8528501, Japan
来源：
IJU CASE REPORTS | 2024年 / 7卷 / 04期
关键词：
end-stage renal disease; enfortumab vedotin; hemodialysis; metastatic urothelial carcinoma;
D O I：
10.1002/iju5.12736
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
IntroductionFew studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.Case presentationCase 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.ConclusionThe efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.
引用
收藏
页码：324 / 328
页数：5
相关论文
共 14 条
  • [1] Prognostic score predicts overall survival following complete urinary tract extirpation
    Akand, Murat
    Muilwijk, Tim
    Van Der Aa, Frank
    Gevaert, Thomas
    Milenkovic, Uros
    Moris, Lisa
    Blyweert, Wim
    Van Poppel, Hendrik
    Albersen, Maarten
    Joniau, Steven
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2020, 54 (01) : 70 - 79
  • [2] Oncological control following laparoscopic nephroureterectomy: 7-year outcome
    Bariol, SV
    Stewart, GD
    McNeill, SA
    Tolley, DA
    [J]. JOURNAL OF UROLOGY, 2004, 172 (05) : 1805 - 1808
  • [3] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [4] FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
    Chang, Elaine
    Weinstock, Chana
    Zhang, Lijun
    Charlab, Rosane
    Dorff, Sarah E.
    Gong, Yutao
    Hsu, Vicky
    Li, Fang
    Ricks, Tiffany K.
    Song, Pengfei
    Tang, Shenghui
    Waldron, Peter E.
    Yu, Jingyu
    Zahalka, Eias
    Goldberg, Kirsten B.
    Pazdur, Richard
    Theoret, Marc R.
    Ibrahim, Amna
    Beaver, Julia A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (04) : 922 - 927
  • [5] Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin
    Choules, Mary P.
    Zuo, Peiying
    Otsuka, Yukio
    Garg, Amit
    Tang, Mei
    Bonate, Peter
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (05) : 417 - 428
  • [6] Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants
    Fan, Yu
    Li, Qinhan
    Shen, Qi
    Liu, Zhifu
    Zhang, Zhenan
    Hu, Shuai
    Yu, Wei
    He, Zhisong
    He, Qun
    Zhang, Qian
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes
    Hoffman-Censits, Jean H.
    Lombardo, Kara A.
    Parimi, Vamsi
    Kamanda, Sonia
    Choi, Woonyoung
    Hahn, Noah M.
    McConkey, David J.
    McGuire, Bridget M.
    Bivalacqua, Trinity J.
    Kates, Max
    Matoso, Andres
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (08) : 619 - 625
  • [8] Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
    Isoda, Bunpei
    Shiga, Masanobu
    Kandori, Shuya
    Nagumo, Yoshiyuki
    Yoshino, Takayuki
    Ikeda, Atsushi
    Kawahara, Takashi
    Kimura, Tomokazu
    Negoro, Hiromitsu
    Hoshi, Akio
    Mathis, Bryan J.
    Nishiyama, Hiroyuki
    [J]. CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 429 - 433
  • [9] Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience
    Nanni, Laura
    Pellegrini, Cinzia
    Stefoni, Vittorio
    Argnani, Lisa
    Cavo, Michele
    Zinzani, Pier Luigi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (11) : E595 - E596
  • [10] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) : 1125 - 1135
12